XML 38 R26.htm IDEA: XBRL DOCUMENT
v3.20.2

Note 1 - Organization, Description of Business and Summary of Significant Accounting Policies (Details Textual) |  |  |  | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | ---
May 13, 2020 USD ($) | May 07, 2019 USD ($) $ / shares shares | Dec. 28, 2018 USD ($) | Jun. 30, 2020 USD ($) $ / shares | Jun. 30, 2019 USD ($) $ / shares | Mar. 31, 2019 USD ($) | Jun. 30, 2020 USD ($) $ / shares | Jun. 30, 2019 USD ($) $ / shares | Dec. 31, 2019 USD ($)
Number of Operating Segments |  |  |  |  |  |  | 1 |  |
Number of Disease Areas with Genomic Testing |  |  |  | 4 |  |  | 4 |  |
Stock Issued During Period, Shares, New Issues (in shares) | shares |  | 6,325,000 |  |  |  |  |  |  |
Sale of Stock, Price Per Share (in dollars per share) | $ / shares |  | $ 23.25 |  |  |  |  |  |  |
Proceeds from Issuance of Common Stock |  | $ 137,800,000 |  |  |  |  | $ 0 | $ 137,848,000 |
Payments of Stock Issuance Costs |  | $ 9,200,000 |  |  |  |  |  |  |
Restricted Cash and Cash Equivalents, Noncurrent, Total |  |  |  | $ 603,000 |  |  | 603,000 |  | $ 603,000
Revenue from Contract with Customer, Excluding Assessed Tax, Total |  |  |  | 20,704,000 | $ 30,136,000 |  | 51,826,000 | 59,665,000 |
Operating Income (Loss), Total |  |  |  | $ (11,051,000) | $ (3,100,000) |  | $ (23,251,000) | $ (5,167,000) |
Earnings Per Share, Basic and Diluted, Total (in dollars per share) | $ / shares |  |  |  | $ (0.22) | $ (0.05) |  | $ (0.45) | $ (0.10) |
Inventory Write-down |  |  |  |  |  |  | $ 1,088,000 | $ 0 |
Loxo Oncology Inc [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |
Contract Agreement, Term (Year) |  |  |  |  |  |  | 1 year |  |
Contract Agreement, Automatic Renewal Term (Year) |  |  |  |  |  |  | 1 year |  |
Contract Agreement, Termination Period (Day) |  |  |  |  |  |  | 90 days |  |
Contract with Customer, Liability, Revenue Recognized |  |  |  |  |  |  | $ 0 |  | 0
Johnson and Johnson Services Inc JJSI [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax, Total |  |  |  | $ 1,300,000 |  |  |  |  |
Contract with Customer, Liability, Revenue Recognized |  |  |  |  |  |  | 0 |  | 0
Collaborative Agreement, Amount |  |  | $ 7,000,000.0 |  |  |  |  |  |
Collaborative Agreement, Contingent Receivable Amount |  |  | $ 13,000,000.0 |  |  |  |  |  |
Collaborative Agreement, Period of Payments After First Commercial (Year) |  |  | 10 years |  |  |  |  |  |
Collaborative Agreement, Fee Percentage of Cash Collections |  |  | 1.00% |  |  |  |  |  |
Accounts Receivable, after Allowance for Credit Loss, Total |  |  |  | 500,000 |  |  | 500,000 |  | 2,000,000.0
Acerta Pharma BV [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax, Total |  |  |  | 200,000 |  |  | 400,000 |  |
Accounts Receivable, after Allowance for Credit Loss, Total |  |  |  | 1,400,000 |  |  | 1,400,000 |  |
Revenue from Achievement of Development Milestones |  |  |  | 1,000,000.0 |  |  |  |  |
CareDx [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax, Total |  |  |  | 1,000,000.0 |  |  |  |  |
Accounts Receivable, after Allowance for Credit Loss, Total |  |  |  | 0 |  |  | 0 |  |
Contract with Customer, Liability, Total | $ 1,000,000.0 |  |  | 0 |  |  | 0 |  |
Commercial Development Agreement, Maximum Payments Receivable from Counter Party Upon Achievement of Milestones | 4,500,000 |  |  |  |  |  |  |  |
Value of Support Services to Counter Party | $ 500,000 |  |  |  |  |  |  |  |
Testing [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax, Total |  |  |  | 15,212,000 | $ 26,686,000 |  | 42,203,000 | 52,075,000 |
Testing [Member] | Cost of Sales [Member] | COVID 19 Pandemic [Member] |  |  |  |  |  |  |  |  |
Inventory Write-down |  |  |  | 1,100,000 |  |  |  |  |
Testing [Member] | Revenue Recognition [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax, Total |  |  |  | 900,000 | 100,000 |  | 700,000 | 800,000 |
Operating Income (Loss), Total |  |  |  | $ 900,000 | $ 100,000 |  | $ 700,000 | $ 800,000 |
Earnings Per Share, Basic and Diluted, Total (in dollars per share) | $ / shares |  |  |  | $ 20,000.00 | $ 0.01 |  | $ 0.01 | $ 0.02 |
Collaborative [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax, Total |  |  |  | $ 0 |  |  | $ 0 |  |
Product [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax, Total |  |  |  | 1,713,000 | $ 0 |  | 5,122,000 | $ 0 |
Product [Member] | Loxo Oncology Inc [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |
Contract with Customer, Liability, Revenue Recognized |  |  |  |  | 0 | $ 90,000 | 0 |  |
Service [Member] | Loxo Oncology Inc [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |
Contract with Customer, Liability, Revenue Recognized |  |  |  | $ 250,000 |  |  | $ 500,000 |  |
Percepta v2 [Member] | Johnson and Johnson Services Inc JJSI [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax, Total |  |  |  |  | 1,200,000 |  |  | 5,000,000.0 |
Fulfillment of Obligations Relating to Percepta v.2 Development Milestones [Member] | Johnson and Johnson Services Inc JJSI [Member] | Collaborative Arrangement [Member] |  |  |  |  |  |  |  |  |
Revenue from Contract with Customer, Excluding Assessed Tax, Total |  |  |  |  | $ 2,000,000.0 |  |  |  |
Overnight Reverse Repurchase Agreements [Member] |  |  |  |  |  |  |  |  |
Cash Equivalents, Percentage Collateralized by US Treasury and Agency Securities |  |  |  | 102.00% |  |  | 102.00% |  |
Cash Equivalents, at Carrying Value, Total |  |  |  | $ 0 |  |  | $ 0 |  |
Collateral for Irrevocable Standby Letter of Credit [Member] |  |  |  |  |  |  |  |  |
Restricted Cash and Cash Equivalents, Noncurrent, Total |  |  |  | $ 603,000 |  |  | $ 603,000 |  | $ 603,000
Over-Allotment Option [Member] |  |  |  |  |  |  |  |  |
Stock Issued During Period, Shares, New Issues (in shares) | shares |  | 825,000 |  |  |  |  |  |  |
Revision of Prior Period, Adjustment [Member] |  |  |  |  |  |  |  |  |
Increase (Decrease) in Operating Capital, Total |  |  |  |  |  |  |  | $ 431,000 |

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(5)) -URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_CashEquivalentsAtCarryingValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256 + Details
Name: | us-gaap_EarningsPerShareBasicAndDiluted
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The increase (decrease) during the reporting period of all assets and liabilities used in operating activities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_IncreaseDecreaseInOperatingCapital
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314 + Details
Name: | us-gaap_InventoryWriteDown
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599 + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow for cost incurred directly with the issuance of an equity security. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585 + Details
Name: | us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 954 -SubTopic 210 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580 + Details
Name: | us-gaap_RestrictedCashAndCashEquivalentsNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of cash equivalents collateralized by US treasury and agency securities. + References No definition available. + Details
Name: | vcyt_CashEquivalentsPercentageCollateralizedByUSTreasuryAndAgencySecurities
Namespace Prefix: | vcyt_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of the collaborative agreement. + References No definition available. + Details
Name: | vcyt_CollaborativeAgreementAmount
Namespace Prefix: | vcyt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of contingent receivable under the collaborative agreement. + References No definition available. + Details
Name: | vcyt_CollaborativeAgreementContingentReceivableAmount
Namespace Prefix: | vcyt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of cash collections that are to be paid under the collaborative agreement. + References No definition available. + Details
Name: | vcyt_CollaborativeAgreementFeePercentageOfCashCollections
Namespace Prefix: | vcyt_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The period of payments commencing after the first commercial under the collaborative agreement. + References No definition available. + Details
Name: | vcyt_CollaborativeAgreementPeriodOfPaymentsAfterFirstCommercial
Namespace Prefix: | vcyt_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum payments that receivable from the counter party upon the achievement of commercial milestones. + References No definition available. + Details
Name: | vcyt_CommercialDevelopmentAgreementMaximumPaymentsReceivableFromCounterPartyUponAchievementOfMilestones
Namespace Prefix: | vcyt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The period of the automatic renewal term of the contract agreement. + References No definition available. + Details
Name: | vcyt_ContractAgreementAutomaticRenewalTerm
Namespace Prefix: | vcyt_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period of the contract agreement. + References No definition available. + Details
Name: | vcyt_ContractAgreementTerm
Namespace Prefix: | vcyt_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The minimum notice period for termination of the contract agreement. + References No definition available. + Details
Name: | vcyt_ContractAgreementTerminationPeriod
Namespace Prefix: | vcyt_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of disease areas with genomic testing. + References No definition available. + Details
Name: | vcyt_NumberOfDiseaseAreasWithGenomicTesting
Namespace Prefix: | vcyt_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of revenue recognized for achievement of development milestones. + References No definition available. + Details
Name: | vcyt_RevenueFromAchievementOfDevelopmentMilestones
Namespace Prefix: | vcyt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The value of support services to the counter party pursuant to the agreement. + References No definition available. + Details
Name: | vcyt_ValueOfSupportServicesToCounterParty
Namespace Prefix: | vcyt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=vcyt_LoxoOncologyIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vcyt_JohnsonAndJohnsonServicesIncJjsiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vcyt_AcertaPharmaBvMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vcyt_CareDxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vcyt_TestingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_UnusualOrInfrequentItemAxis=vcyt_Covid19PandemicMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ChangeInAccountingEstimateByTypeAxis=vcyt_RevenueRecognitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vcyt_CollaborativeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vcyt_PerceptaV2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vcyt_FulfillmentOfObligationsRelatingToPerceptaV2DevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CashAndCashEquivalentsAxis=vcyt_OvernightReverseRepurchaseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CashAndCashEquivalentsAxis=vcyt_CollateralForIrrevocableStandbyLetterOfCreditMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RestatementAxis=srt_RestatementAdjustmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |